Which Granulation Route Preserves Lincomycin HCl Tablet Dissolution at 500 mg Label Claim?

For a high-dose oral tablet containing lincomycin hydrochloride monohydrate equivalent to 500 mg lincomycin base, the active constituent represents 56–67% w/w of the uncoated core when total core mass is held between 850 mg and 1000 mg. That high active fraction makes dry blending and direct compression flow-critical because lincomycin hydrochloride monohydrate is freely soluble in water and exhibits surface moisture uptake at relative humidity above 60% RH. Aqueous wet granulation is therefore selected when the downstream tablet needs a disintegration time below 15 min in purified water at 37 °C under USP <701> conditions. The process starts with high-shear granulation in a 300 L horizontal granulator at impeller speed 200–300 rpm and chopper speed 1500–3000 rpm; povidone K30 is dissolved in purified water at 5–8% w/w binder solution concentration and sprayed at 2–4% w/w dry binder content. Wet massing is limited to 3–6 min and the granules are discharged at a loss-on-drying of 1.5–2.5%, milled through a 1.0–1.5 mm screen, and dried in a fluid-bed dryer with inlet air at 60–70 °C and product temperature 35–45 °C to a final moisture specification of 1.0–2.5%. Tablet compression on a rotary press uses precompression 5–10 kN, main compression 15–25 kN, and target hardness 80–150 N. Crospovidone at 2–4% w/w and microcrystalline cellulose at 20–30% w/w are used to maintain tablet porosity; magnesium stearate is restricted to 0.5–1.5% w/w and blended for 3–5 min to avoid hydrophobic coating. Aqueous film coating with hydroxypropyl methylcellulose-based Opadry II is applied at 3–4% w/w weight gain with inlet temperature 65–75 °C, bed temperature 38–45 °C, and pan speed 6–10 rpm. Release testing follows USP <711> dissolution, USP <905> uniformity of dosage units, USP <921> water determination, and ICH Q3D elemental impurities; batch release also requires FDA 21 CFR 211.165 and 211.166 testing. The terminal finished dosage types are immediate-release film-coated tablets labeled at 250 mg or 500 mg lincomycin base.

In capsule manufacturing, the 500 mg lincomycin base dose creates a dry blend with an active salt fraction of 70–81% w/w when the target fill weight is 700–800 mg per size 0 or 00 hard gelatin capsule. The active particle size distribution is controlled at 50–150 µm, because finer material increases cohesiveness and coarser material retards dissolution; the blend is not suitable for direct encapsulation without a granulation step because flow through a dosator nozzle becomes erratic at Carr’s index above 25%. A roller-compacted dry granulation route is therefore specified: the API is premixed with microcrystalline cellulose 10–20% w/w, lactose monohydrate 5–15% w/w, croscarmellose sodium 2–4% w/w, and colloidal silicon dioxide 0.3–0.8% w/w in a 600 L bin blender at 10 rpm for 20 min. The mixture is passed through a roller compactor at roll pressure 30–50 kN/cm, roll gap 2–4 mm, and roller speed 5–10 rpm; ribbons are milled through a 0.8–1.25 mm screen to produce granules with bulk density 0.55–0.65 g/mL and tapped density 0.70–0.80 g/mL. After lubrication with magnesium stearate 0.5–1.0% w/w for 3–5 min, the granules are filled on an intermittent-motion dosator encapsulator at 60,000–120,000 capsules/h. Because lincomycin hydrochloride monohydrate is hygroscopic, the granulation bay is maintained at 35–45% RH and the final granule moisture is controlled to 1.0–2.0% by Karl Fischer titration according to USP <921>. Release testing includes USP <711> dissolution with apparatus 2 paddle at 50 rpm, USP <905> content uniformity, USP <701> disintegration, ICH Q3C residual solvents, and 21 CFR 211.110 in-process control. The terminal finished dosage type is the hard gelatin capsule containing lincomycin hydrochloride monohydrate equivalent to 500 mg lincomycin base.

Aseptic Filtration of Lincomycin HCl Injection Cannot Deviate from EU GMP Annex 1 Grade A Contact Points

For sterile injectable solution, lincomycin hydrochloride monohydrate is dissolved in Water for Injection to achieve 300 mg/mL lincomycin base. Because the molecular weight of lincomycin hydrochloride monohydrate is 461.0 g/mol and lincomycin base is 406.5 g/mol, each litre of formulated solution contains 340.2 g of the monohydrate salt. The compounding vessel is 316L stainless steel with a chilled water jacket, and dissolution is performed at 15–25 °C with continuous recirculation through a 0.45 µm prefilter. The pH is adjusted with 1 M sodium hydroxide or hydrochloric acid to a target of 4.0–6.0, because acidic pH suppresses hydrolysis of the lincomycin amide bond and reduces related degradation products; the solution is held under nitrogen overlay with headspace oxygen maintained below 2% v/v. The solution is sterile-filtered through two 0.22 µm PVDF membrane filters in series, then aseptically filled into depyrogenated Type I borosilicate glass vials or ampoules under Grade A laminar airflow with Grade B background as required by EU GMP Annex 1 and FDA 21 CFR 211.113(b). Fill volume is controlled to 2 mL, 5 mL, 10 mL, or 20 mL; for multi-dose presentations, an antimicrobial preservative such as benzyl alcohol may be included at its pharmacopoeial permitted concentration, but only where regional licensing permits and only after preservative efficacy testing under USP <51>. Release testing includes USP <71> sterility, USP <85> bacterial endotoxins, USP <788> particulate matter in injections, USP <790> visible particulates, and ICH Q3D elemental impurities. Because published data for terminal sterilization of this specific lincomycin hydrochloride solution is limited, aseptic filtration remains the default route and thermal exposure must be validated before terminal sterilization is introduced. The terminal finished dosage types are sterile injectable solution vials, ampoules, and multi-dose vials labeled at 300 mg/mL lincomycin base equivalent.

Where national drug registers include lincomycin hydrochloride as a dry granule for oral suspension, the granule design is driven by the need to mask the intense bitterness of the API and to deliver a reconstituted concentration of 250 mg/5 mL lincomycin base. A representative 100 g granule batch containing 5.67 g lincomycin hydrochloride monohydrate would deliver 5.00 g lincomycin base after reconstitution to 100 mL, corresponding to 50 mg/mL or 250 mg/5 mL. The carrier system typically comprises sucrose or sorbitol at 70–85% w/w, xanthan gum 0.2–0.4% w/w, sodium carboxymethylcellulose 0.5–1.0% w/w, citric acid 0.1–0.3% w/w, sodium citrate 0.1–0.3% w/w, and a volatile mint or cherry flavor. The granulation process uses a hydroalcoholic binder solution containing povidone K30 at 2–4% w/w; wet mass is passed through a 1.0 mm screen, dried in a fluid-bed dryer at inlet 55–65 °C to final moisture below 1.5%, and sized through 16–40 mesh. The finished granules are packed into aluminum foil laminate sachets at 10 g, 20 g, or 100 g fill weights. Published compendial monographs for this specific lincomycin hydrochloride granule presentation are limited in several regions; therefore, release specifications are derived from the general monograph for oral powders and from ICH Q1A stability, ICH Q3B degradation products, and ICH Q3D elemental impurities, with USP <711> dissolution applied after reconstitution where justified. The terminal finished dosage types are single-dose or multi-dose sachets for reconstitution to an oral suspension.

When Lincomycin Hydrochloride Is Formulated as a Drinking-Water Powder for Swine and Poultry

In veterinary drinking-water formulations, lincomycin hydrochloride monohydrate is dry-blended with anhydrous citric acid, lactose monohydrate, and silica to produce a water-soluble powder with rapid dispersion. A typical 100 g sachet is formulated to contain 20–40 g lincomycin base equivalent, corresponding to 22.7–45.4 g lincomycin hydrochloride monohydrate; the product is administered through drinking water at a target concentration of 50–150 mg/L for growing pigs and poultry depending on the approved veterinary indication. Dry blending is performed in a 500 L ribbon blender at 20–30 rpm for 25–35 min; the mixture is deagglomerated through a 0.8 mm screen and filled into polyethylene-aluminum-foil laminate sachets under nitrogen. Dissolution performance is checked by adding a single sachet to 100 L of purified water at 20 °C, and complete dispersion must occur within 2 min without sedimentation; pH after dispersion is controlled to 3.5–5.5 to reduce hydrolysis of the lincomycin amide bond. Compliance for this non-sterile veterinary product is evaluated under Regulation (EU) 2019/6, ICH Q3C residual solvents, and ICH Q3D elemental impurities adapted under VICH guidance; in-process controls for blend uniformity and moisture follow 21 CFR 211.110. The terminal finished dosage types are water-soluble powder sachets for oral administration in drinking water for swine and poultry.